Myocardial infarction, heart failure and sympathetic nervous system activity: New approaches that affect neurohumoral activation

Expert Opinion on Investigational Drugs

Volumn 17, Issue 9, 2008, Pages 1315-1330

  Ciarka, Agnieszka ^a   van de Borne, Philippe ^a   Pathak, Atul ^b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Aldosterone system; Heart failure; Myocardial infarction; Renin angiotensin; Sympathetic activation

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BUCINDOLOL; CALCIUM ANTAGONIST; CARVEDILOL; CATECHOLAMINE; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; IVABRADINE; LEVOSIMENDAN; LIDOCAINE; MAGNESIUM; NAXIFYLLINE; NITRIC ACID DERIVATIVE; OMAPATRILAT; PLACEBO; PROPRANOLOL; PROTEIN TYROSINE KINASE INHIBITOR; QUINAPRIL; RENIN INHIBITOR; TOLVAPTAN; UNINDEXED DRUG; VERAPAMIL;

ACUTE HEART INFARCTION; ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; ANGIONEUROTIC EDEMA; ANGIOPLASTY; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG TARGETING; EXERCISE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART RATE VARIABILITY; HEART REHABILITATION; HEART SCINTISCANNING; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISOTOPE LABELING; LONG TERM CARE; LOW DRUG DOSE; NERVE CONDUCTION; NEUROMODULATION; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION; REVIEW; RISK ASSESSMENT; SYMPATHETIC TONE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; PHARMACEUTICAL PREPARATIONS; SYMPATHETIC NERVOUS SYSTEM;

EID: 52949147453     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.9.1315     Document Type: Review

References (130)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update; 2005
2. Thom T, Kannel W, Silbershatz S. Incidence, prevalence and mortality of cardiovascular diseases in the United States. In: Alexander R, Schlant R, Fuster V, Roberts R, editors. Hurst's the heart. New York: McGraw Hill; 1998. p. 3
3. Esler M, Kaye D. Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev 2000;5:17-25
4. Leimbach WN Jr, Wallin BG, Victor RG, et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-9
5. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension 1988;11:608-12
6. Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;110:1308-12
7. Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323:693-9
8. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63
9. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988;84:61-6
10. La Rovere MT, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478-84
11. Graham LN, Smith PA, Stoker JB, et al. Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation 2002;106:793-7
12. Baker PF, Knight DE. Calcium-dependent exocytosis in bovine adrenal medullary cells with leaky plasma membranes. Nature 1978;276:620-2
13. Schomig A. Catecholamines in myocardial ischemia. Systemic and cardiac release. Circulation 1990;82:II13-22
14. Videbaek J, Christensen NJ, Sterndorff B. Serial determination of plasma catecholamines in myocardial infarction. Circulation 1972;46:846-55
15. Griffi ths J, Leung F. The sequential estimation of plasma catecholamines and whole blood histamine in myocardial infarction. Am Heart J 1971;82:171-9
16. Siggers DC, Salter C, Fluck DC. Serial plasma adrenaline and noradrenaline levels in myocardial infarction using a new double isotope technique. Br Heart J 1971;33:878-83
17. Esler M, Jennings G, Korner P, et al. Measurement of total and organ-specific norepinephrine kinetics in humans. Am J Physiol 1984;247:E21-8
18. Karlsberg RP, Cryer PE, Roberts R. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J 1981;102:24-9
19. Bertel O, Buhler FR, Baitsch G, et al. Plasma adrenaline and noradrenaline in patients with acute myocardial infarction. Relationship to ventricular arrhythmias of varying severity. Chest 1982;82:64-8
20. Schoemig A, Ness G, Mayer E, et al. Sympathetic activity in patients with acute myocardial infarction before and after intracoronary thrombolytic therapy. Eur Heart J 1984;5(Suppl 1):39
21. Benedict CR, Grahame-Smith DG. Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J 1979;42:214-20
22. Uchida Y, Murao S. Excitation of afferent cardiac sympathetic nerve fibers during coronary occlusion. Am J Physiol 1974;226:1094-9
23. Thames MD, Klopfenstein HS, Abboud FM, et al. Preferential distribution of inhibitory cardiac receptors with vagal afferents to the inferoposterior wall of the left ventricle activated during coronary occlusion in the dog. Circ Res 1978;43:512-9
24. Dart AM, Schomig A, Dietz R, et al. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part B. Effect of sympathetic nerve stimulation. Circ Res 1984;55:702-6
25. Iversen LL. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 1971;41:571-91
26. Richardt G, Waas W, Kranzhofer R, et al. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res 1987;61:117-23
27. Schomig A. Adrenergic mechanisms in myocardial infarction: cardiac and systemic catecholamine release. J Cardiovasc Pharmacol 1988;12(Suppl 1):S1-7
28. Schomig A, Dart AM, Dietz R, et al. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A. Locally mediated release. Circ Res 1984;55:689-701
29. Waldenstrom AP, Hjalmarson AC, Thornell L. A possible role of noradrenaline in the development of myocardial infarction: an experimental study in the isolated rat heart. Am Heart J 1978;95:43-51
30. Strasser RH, Krimmer J, Braun-Dullaeus R, et al. Dual sensitization of the adrenergic system in early myocardial ischemia: independent regulation of the beta-adrenergic receptors and the adenylyl cyclase. J Mol Cell Cardiol 1990;22:1405-23
31. Schomig A, Fischer S, Kurz T, et al. Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements. Circ Res 1987;60:194-205
32. Toll L, Howard BD. Role of Mg2+-ATPase and a pH gradient in the storage of catecholamines in synaptic vesicles. Biochemistry 1978;17:2517-23
33. Fiolet JW, Baartscheer A, Schumacher CA, et al. The change of the free energy of ATP hydrolysis during global ischemia and anoxia in the rat heart. Its possible role in the regulation of transsarcolemmal sodium and potassium gradients. J Mol Cell Cardiol 1984;16:1023-36
34. Stute N, Trendelenburg U. The outward transport of axoplasmic noradrenaline induced by a rise of the sodium concentration in the adrenergic nerve endings of the rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol 1984;327:124-32
35. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J. 1993;126:1068-76
36. Schwartz PJ, Zaza A, Pala M, et al. Baroreflex sensitivity and its evolution during the first year after myocardial infarction. J Am Coll Cardiol 1988;12:629-36
37. Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol 1991;18:1643-9
38. Graham LN, Smith PA, Stoker JB, et al. Sympathetic neural hyperactivity and its normalization following unstable angina and acute myocardial infarction. Clin Sci (Lond) 2004;106:605-11
39. Thames MD, Dibner-Dunlap ME, Minisi AJ, Kinugawa T. Reflexes mediated by cardiac sympathetic afferents during myocardial ischaemia: role of adenosine. Clin Exp Pharmacol Physiol 1996;23:709-14
40. Malliani A, Montano N. Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions. Hypertension 2002;39:63-8
41. Minisi AJ, Thames MD. Effect of chronic myocardial infarction on vagal cardiopulmonary baroreflex. Circ Res 1989;65:396-405
42. Thames MD, Abboud FM. Reflex inhibition of renal sympathetic nerve activity during myocardial ischemia mediated by left ventricular receptors with vagal afferents in dogs. J Clin Invest 1979;63:395-402
43. Wieland DM, Wu J, Brown LE, et al. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53
44. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7
45. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78:1192-9
46. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31
47. Sisson JC, Johnson J, Bolgos G, et al. Portrayal of adrenergic denervation in the presence of myocardial infarction: a feasibility study. Am J Physiol Imaging 1990;5:151-66
48. Yuyama R, Yuasa F, Hikosaka M, et al. Iodine 123-metaiodobenzylguanidine imaging reflect generalized sympathetic activation in patients with left ventricular dysfunction. Clin Physiol Funct Imaging 2005;25:34-9
49. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90
50. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995;92:3206-11
51. Grassi G, Mancia G. Sympathetic overactivity and exercise intolerance in heart failure: a cause-effect relationship. Eur Heart J 1999;20:854-55
52. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971;285:877-83
53. Zucker IH, Wang W, Brandle M, et al. Neural regulation of sympathetic nerve activity in heart failure. Prog Cardiovasc Dis 1995;37:397-414
54. Levine TB, Francis GS, Goldsmith SR, Cohn JN. The neurohumoral and hemodynamic response to orthostatic tilt in patients with congestive heart failure. Circulation 1983;67:1070-5
55. Newton GE, Parker JD. Cardiac sympathetic responses to acute vasodilation. Normal ventricular function versus congestive heart failure. Circulation 1996;94:3161-7
56. Ponikowski P, Chua TP, Piepoli M, et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 1997;96:2586-94
57. Narkiewicz K, Pesek CA, van de Borne PJ, et al. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Circulation 1999;100:262-7
58. Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol 1991;18:1643-9
59. Malliani A, Recordati G, Schwartz PJ. Nervous activity of afferent cardiac sympathetic fi bres with atrial and ventricular endings. J Physiol 1973;229:457-69
60. Wolf MM, Varigos GA, Hunt D, Sloman JG. Sinus arrhythmia in acute myocardial infarction. Med J Aust 1978;2:52-3
61. Soejima K, Akaishi M, Meguro T, et al. Age-adjusted heart rate variability as an index of the severity and prognosis of heart failure. Jpn Circ J 2000;64:32-8
62. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998;98:1510-6
63. Burger AJ, Aronson D. Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure. J Card Fail 2001;7:122-8
64. Malfatto G, Blengino S, Annoni L, et al. Original articles primary coronary angioplasty and subsequent cardiovascular rehabilitation are linked to a favorable sympathovagal balance after a first anterior myocardial infarction. Ital Heart J 2005;6:21-7
65. Bonnemeier H, Hartmann F, Wiegand UK, et al. Heart rate variability in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2000;85:815-20
66. Vogt A, Vetterlein F, dal Ri H, Schmidt G. Excitation of afferent fibres in the cardiac sympathetic nerves induced by coronary occlusion and injection of bradykinin. The influence of acetylsalicylic acid and dipyron. Arch Int Pharmacodyn Ther 1979;239:86-98
67. Jacobsen TN, Converse RL Jr, Victor RG. Contrasting effects of propranolol on sympathetic nerve activity and vascular resistance during orthostatic stress. Circulation 1992;85:1072-6
68. Nagata Y. Flecainide augments muscle sympathetic nerve activity in humans. Circ J 2002;66:377-81
69. Kurz T, Richardt D, Gorge B, et al. Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. J Cardiovasc Pharmacol 2000;36:96-100
70. Morita K, Hamano S, Yoshizumi M, Oka M. Inhibitory action of carvedilol, a novel alpha, beta-adrenoceptor antagonist, on catecholamine secretion and calcium influx in cultured bovine adrenal chromaffin cells. Biochem Pharmacol 1989;38:4461-5
71. Persson H, Andreasson K, Kahan T, et al. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail 2002;4:73-82
72. De Matos LD, Gardenghi G, Rondon MU, et al. Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. J Card Fail 2004;10:496-502
73. Copie X, Pousset F, Lechat P, et al. Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. Am Heart J 1996;132:369-75
74. Abboud FM, Mark AL, Thames MD. Modulation of the somatic reflex by carotid baroreceptors and by cardiopulmonary afferents in animals and in humans. Circ Res 1981;48:I131-7
75. Grassi G, Giannattasio C, Cuspidi C, et al. Cardiopulmonary receptor regulation of renin release. Am J Med 1988;84:97-104
76. Grassi G, Giannattasio C, Seravalle G, et al. Cardiopulmonary receptor and arterial baroreceptor reflexes after acute myocardial infarction. Am J Cardiol 1992;69:873-8
77. Hikosaka M, Yuasa F, Yuyama R, et al. Effect of angiotensin-converting enzyme inhibitor on cardiopulmonary baroreflex sensitivity in patients with acute myocardial infarction. Am J Cardiol 2000;86:1241-4, A6
78. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992;262:E763-78
79. Hayashi J, Takeda K, Kawasaki S, et al. Central attenuation of baroreflex by angiotensin II in normotensive and spontaneously hypertensive rats. Am J Hypertens 1988;1:S15-22
80. De Tommasi E, Iacoviello M, Romito R, et al. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 2003;146:E17
81. Struck J, Muck P, Trubger D, et al. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002;20:1143-9
82. Ebert TJ, Mohanty PK, Kampine JP. Lidocaine attenuates efferent sympathetic responses to stress in humans. J Cardiothorac Vasc Anesth 1991;5:437-43
83. Vaage-Nilsen M, Rasmussen V. Effect of verapamil on heart rate variability after an acute myocardial infarction. Danish Verapamil Infarction Trial II. Cardiovasc Drugs Ther 1998;12:285-90
84. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44
85. Mimura J, Yuasa F, Yuyama R, et al. The effect of residential exercise training on baroreflex control of heart rate and sympathetic nerve activity in patients with acute myocardial infarction. Chest 2005;127:1108-15
86. Guo GB, Abboud FM. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol 1984;246:H80-9
87. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-5
88. Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep 2004;1:45-50
89. Backs J, Bresch E, Lutz M, et al. Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats. Cardiovasc Res 2005;67:283-90
90. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006;103:11288-93
91. Schwartzenberg S, Ben Shoshan J, Keren G, George J. The role of erythropoietin in myocardial protection: potential mechanisms and applications. Expert Rev Cardiovasc Ther 2006;4:41-50
92. Fox K, Ferrari R, Tendera M, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006;152:860-6
93. Gottlieb SS. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs 2001;61:1387-93
94. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-53
95. Gottlieb SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000;35:56-9
96. Kitakaze M, Hori M. Adenosine therapy: a new approach to chronic heart failure. Expert Opin Investig Drugs 2000;9:2519-35
97. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85
98. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71
99. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V2; vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23
100. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 2003;145:179-86
101. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:G47-58
102. Bragadeesh TKM, Mathur G, Clark AL, Cleland JGF. Novel cardiac myosin activators for acute heart failure. Expert Opin Investig Drugs 2007;16(10):1541-8
103. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91
104. Topol EJ. Nesiritide - not verified. N Engl J Med 2005;353:113-6
105. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5
106. Mitrovic V, Luss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005;150:1239
107. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6
108. Tabrizchi R. Omapatrilat. Bristol-Myers Squibb. Curr Opin Investig Drugs 2001;2:1414-22
109. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76
110. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8
111. Rudolph AE, Rocha R, McMahon EG. Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol 2004;217:229-38
112. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005;10:7-13
113. Sadoshima J, Izumo S. Molecular characterization of angiotensin II - induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23
114. Lautrette A, Li S, Alili R, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005;11:867-74
115. Kelly DJ, Cox AJ, Gow RM, et al. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 2004;44:195-202
116. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
117. Vercauteren M, Remy E, Devaux C, et al. Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure. Circulation 2006;114:2498-507
118. Brown MJ, Coltart J, Gunewardena K, et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004;107:167-73
119. Zhu F, Liao YH, Li LD, et al. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006;3:107-14
120. Yoneda M, Sanada H, Yatabe J, et al. Differential effects of angiotensin II type-1 receptor antisense oligonucleotides on renal function in spontaneously hypertensive rats. Hypertension 2005;46:58-65
121. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-8
122. Huang L, Sexton DJ, Skogerson K, et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 2003;278:15532-40
123. Cleland JGF, Coletta AP, Clark AL, et al. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail 2005;7:937-9
124. Geert T, Leen MvW, Molhoek GP, et al. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drug Ther 2001;V15:139-45
125. Pathak A, Curnier D, Fourcade J, et al. QT dynamicity: a prognostic factor for sudden cardiac death in chronic heart failure. Eur J Heart Fail 2005;7:269-75
126. Boveda S, Galinier M, Pathak A, et al. Prognostic value of heart rate variability in time domain analysis in congestive heart failure. J Interv Card Electrophysiol 2001;5:181-7
127. Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J 2000;21:475-82
128. van de Borne P, Montano N, Pagani M, et al. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure. Circulation 1997;95:1449-54
129. Yee KM, Struthers AD. Can drug effects on mortality in heart failure be predicted by any surrogate measure? Eur Heart J 1997;18:1860-4
130. Hunt SA. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82